Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer
Daraxonrasib is a RAS inhibitor from Revolution Medicines that has been approved by the Food & Drug Administration for previously treated pancreatic cancer
This Phase 1/2 trial is the first-in-human study of daraxonrasib in patients with non-small cell lung cancer
RAS mutations are the most common cancer drivers of non-small cell lung cancer, occurring in about 30% of patients
The results of this trial initiated the Phase 3 RASolve...
